REGISTER FOR THIS EVENT
A new chapter in ATTR-CM: Recognising red flags and optimising referrals
Thursday 23rd April 2026, 13:00 - 13:45 BST | To be held virtually
For UK healthcare professionals only. This promotional virtual meeting has been funded and organised by Alnylam UK Limited.
Please note that some of the sessions will include data specific to products from Alnylam UK Limited.
AMVUTTRA® is indicated for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients and cardiomyopathy (ATTR-CM).
AMVUTTRA® is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.
AMVUTTRA® is recommended by NICE as an option for the treatment of transthyretin amyloidosis in adults with cardiomyopathy (TA1115).
AMVUTTRA® is recommended by NICE as an option for the treatment of hATTR in adults with stages 1 or 2 PN (TA868).
A new chapter in ATTR-CM: Recognising red
flags and optimising referrals.
Agenda
13:00 - 13:05 - Welcome and introduction - Professor Marianna Fontana, National Amyloidosis Centre.
13:05 - 13:10 - At the heart of ATTR-CM: redefining first-line therapy with AMVUTTRA® - Professor Marianna Fontana
13:10 - 13:20 - Recognising red flags: a spotlight on carpal tunnel - Dr Yousuf Razvi, National Amyloidosis Centre.
13:20 - 13:30 - Optimising referrals: what does the NAC look for? - Professor Marianna Fontana
13:30 - 13:45 - Q&A - Dr Yousuf Razvi & Professor Marianna Fontana
Register for this event below:
If you have already registered, please join below:
To report an adverse event in the UK:
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard/mhra.gov.uk/ or via the Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Alnylam Pharmaceuticals at 0800 141 2569 (+44 1628 878 592) or medinfo@alnylam.com